See more : Dycom Industries, Inc. (DY) Income Statement Analysis – Financial Results
Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- AVer Information Inc. (3669.TW) Income Statement Analysis – Financial Results
- Commodore Applied Technologies, Inc. (CXIA) Income Statement Analysis – Financial Results
- SEL Manufacturing Company Limited (SELMC.NS) Income Statement Analysis – Financial Results
- Rival Technologies, Inc. (RVTI) Income Statement Analysis – Financial Results
- Yuanta SPAC 16 (474490.KQ) Income Statement Analysis – Financial Results
Sanofi (SNY)
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.03B | 45.39B | 39.18B | 37.37B | 37.63B | 35.68B | 36.22B | 34.70B | 34.86B | 32.00B | 31.29B | 35.96B | 35.06B | 32.04B | 30.75B | 28.82B | 29.25B | 29.49B | 28.49B | 15.03B | 8.03B | 7.46B | 6.49B | 5.96B | 5.35B |
| Cost of Revenue | 14.24B | 13.69B | 12.26B | 12.16B | 11.98B | 11.32B | 11.45B | 10.70B | 10.92B | 10.23B | 10.29B | 11.08B | 10.90B | 8.72B | 7.88B | 7.34B | 7.58B | 7.59B | 7.56B | 3.75B | 1.43B | 1.38B | 1.25B | 1.44B | 1.49B |
| Gross Profit | 31.80B | 31.70B | 26.92B | 25.21B | 25.66B | 24.36B | 24.77B | 24.00B | 23.94B | 21.77B | 21.00B | 24.88B | 24.16B | 23.32B | 22.87B | 21.48B | 21.67B | 21.90B | 20.93B | 11.28B | 6.61B | 6.08B | 5.24B | 4.52B | 3.86B |
| Gross Profit Ratio | 69.07% | 69.83% | 68.72% | 67.47% | 68.18% | 68.27% | 68.40% | 69.16% | 68.68% | 68.03% | 67.10% | 69.20% | 68.90% | 72.79% | 74.37% | 74.55% | 74.08% | 74.27% | 73.47% | 75.05% | 82.26% | 81.50% | 80.69% | 75.82% | 72.11% |
| Research & Development | 6.73B | 6.71B | 5.69B | 5.53B | 6.02B | 6.35B | 5.57B | 5.23B | 5.08B | 4.67B | 4.61B | 4.91B | 4.81B | 4.40B | 4.58B | 4.58B | 4.54B | 4.43B | 4.04B | 7.45B | 1.31B | 1.22B | 1.03B | 945.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00M | 106.00M | 106.00M | 114.00M | -542.00M | -495.00M | 182.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 9.39B | 9.88B | 9.86B | 10.06B | 9.49B | 9.38B | 9.11B | 8.60B | 8.95B | 8.54B | 7.57B | 7.33B | 7.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.77B | 10.54B | 9.56B | 9.39B | 9.88B | 9.93B | 10.16B | 9.59B | 9.50B | 8.57B | 8.11B | 9.13B | 8.54B | 7.57B | 7.33B | 7.17B | 7.87B | 8.02B | 8.24B | 4.50B | 2.47B | 2.43B | 2.31B | 2.02B | 1.89B |
| Other Expenses | 6.45B | 2.57B | 2.53B | 2.40B | 2.53B | 1.70B | 1.66B | 1.65B | 2.23B | 3.02B | 3.13B | 3.02B | 3.62B | 3.58B | 3.14B | -23.00M | 3.20B | 3.45B | 2.93B | -360.73M | -246.94M | -189.64M | -208.00M | -17.00M | 995.00M |
| Operating Expenses | 23.94B | 19.81B | 17.77B | 17.32B | 18.43B | 17.99B | 17.39B | 16.48B | 16.81B | 16.25B | 15.84B | 17.05B | 16.97B | 15.55B | 15.05B | 11.72B | 15.61B | 15.90B | 15.21B | 11.59B | 3.54B | 3.46B | 3.13B | 2.94B | 2.89B |
| Cost & Expenses | 38.16B | -7.29B | 30.03B | 29.48B | 30.41B | -7.73B | -7.42B | -7.18B | -7.44B | -5.64B | -5.86B | -7.29B | 27.87B | 24.27B | 22.93B | 19.06B | 23.20B | 23.49B | 22.77B | 15.34B | 4.96B | 4.84B | 4.38B | 4.39B | 4.38B |
| Interest Income | 546.00M | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M | 147.00M | 68.00M | 178.00M | 193.00M | 109.00M | 93.00M | 140.00M | 105.00M | 24.00M | 65.00M | 190.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.09B | 461.00M | 368.00M | 390.00M | 444.00M | 495.00M | 420.00M | 924.00M | 559.00M | 598.00M | 609.00M | 751.00M | 552.00M | 467.00M | 324.00M | 335.00M | 329.00M | 1.54B | 4.71B | 2.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.78B | 3.70B | 3.13B | 3.27B | 3.75B | 3.46B | 3.15B | 2.99B | -2.48B | -2.75B | -3.39B | -3.20B | 4.91B | 5.44B | 5.00B | 245.00M | 4.48B | 6.73B | 5.95B | 2.52B | 117.52M | 179.16M | 301.00M | 241.00M | 236.00M |
| EBITDA | 12.00B | 14.06B | 11.29B | 17.51B | 7.11B | 9.36B | 10.28B | 10.36B | 10.23B | 9.87B | 9.62B | 11.43B | 10.64B | 11.40B | 11.40B | 10.48B | 10.40B | 12.12B | 11.67B | 2.25B | 3.19B | 3.00B | 2.41B | 1.82B | 1.21B |
| EBITDA Ratio | 26.06% | 30.98% | 27.47% | 26.13% | 26.15% | 26.24% | 28.38% | 29.86% | 29.36% | 30.84% | 30.74% | 34.77% | 30.35% | 35.59% | 36.98% | 34.73% | 35.56% | 42.26% | 47.01% | 14.99% | 39.67% | 37.49% | 37.10% | 30.49% | 22.56% |
| Operating Income | 7.88B | 16.79B | 8.13B | 8.08B | 7.69B | 12.43B | 12.01B | 12.34B | 12.71B | 12.62B | 13.01B | 15.70B | 5.73B | 5.96B | 6.37B | 9.76B | 5.92B | 5.73B | 7.45B | -262.61M | 3.07B | 2.62B | 2.11B | 1.58B | 971.00M |
| Operating Income Ratio | 17.11% | 37.00% | 20.74% | 21.63% | 20.45% | 34.84% | 33.15% | 35.57% | 36.46% | 39.45% | 41.58% | 43.67% | 16.35% | 18.61% | 20.70% | 33.88% | 20.24% | 19.43% | 26.13% | -1.75% | 38.21% | 35.09% | 32.46% | 26.45% | 18.15% |
| Total Other Income/Expenses | -722.00M | -166.00M | -328.00M | 24.00M | -229.00M | 228.00M | -188.00M | -720.00M | -403.00M | -458.00M | -459.00M | -1.81B | -542.00M | -362.00M | -300.00M | -232.00M | -139.00M | -981.21M | -2.11B | -588.67M | 58.76M | -108.64M | 34.00M | -17.00M | -48.00M |
| Income Before Tax | 7.15B | 10.49B | 7.80B | 13.80B | 2.82B | 4.90B | 5.62B | 5.81B | 5.22B | 5.61B | 4.52B | 6.17B | 5.32B | 5.60B | 6.07B | 9.49B | 5.78B | 4.75B | 2.64B | -1.84B | 3.13B | 2.51B | 2.14B | 1.56B | 0.00 |
| Income Before Tax Ratio | 15.54% | 23.11% | 19.91% | 36.94% | 7.50% | 13.75% | 15.50% | 16.75% | 14.98% | 17.52% | 14.45% | 17.15% | 15.17% | 17.48% | 19.73% | 32.94% | 19.76% | 16.10% | 9.27% | -12.25% | 38.94% | 33.63% | 32.98% | 26.16% | 0.00% |
| Income Tax Expense | 1.60B | 2.01B | 1.56B | 1.81B | 139.00M | 481.00M | 1.72B | 1.33B | 709.00M | 1.21B | 726.00M | 1.11B | 455.00M | 1.24B | 1.36B | 2.76B | 687.93M | 800.12M | 477.04M | 818.09M | 1.06B | 747.13M | 842.00M | 611.00M | 346.00M |
| Net Income | 5.40B | 8.37B | 6.22B | 12.29B | 2.81B | 4.31B | 3.89B | 4.71B | 4.29B | 4.39B | 3.72B | 4.97B | 5.69B | 4.36B | 5.27B | 7.19B | 5.27B | 4.01B | 2.26B | -2.66B | 2.07B | 1.76B | 1.59B | 985.00M | 625.00M |
| Net Income Ratio | 11.73% | 18.44% | 15.89% | 32.90% | 7.46% | 12.07% | 10.75% | 13.57% | 12.30% | 13.72% | 11.88% | 13.81% | 16.24% | 13.60% | 17.12% | 24.94% | 18.02% | 13.58% | 7.92% | -17.70% | 25.80% | 23.61% | 24.43% | 16.52% | 11.68% |
| EPS | 4.31 | 6.69 | 4.97 | 9.81 | 2.33 | 3.45 | 3.08 | 3.42 | 3.38 | 3.25 | 2.75 | 3.70 | 4.27 | 3.34 | 4.03 | 2.94 | 3.91 | 2.97 | 1.68 | -2.92 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| EPS Diluted | 4.30 | 6.66 | 4.95 | 9.76 | 2.31 | 3.43 | 3.07 | 3.39 | 3.34 | 3.21 | 2.71 | 3.68 | 4.26 | 3.33 | 4.03 | 2.94 | 3.89 | 2.95 | 1.67 | -2.91 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| Weighted Avg Shares Out | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.29B | 1.32B | 1.32B | 1.32B | 1.33B | 1.32B | 1.31B | 1.31B | 1.31B | 1.35B | 1.35B | 1.34B | 910.30M | 702.75M | 727.69M | 731.71M | 731.23M | 730.78M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.32B | 1.33B | 1.34B | 1.33B | 1.33B | 1.31B | 1.31B | 1.31B | 1.35B | 1.36B | 1.35B | 914.80M | 705.12M | 729.27M | 731.71M | 731.23M | 730.78M |
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Global Fortune 500 Company Doubles Down on Beijing E-Town with Back-to-Back Investments Over Three Years: Insights from the Sanofi Project into E-Town's Business Environment
China's First International Pharma Biotherapeutic API Project Launched in Beijing E-Town -- Sanofi Invests Approximately 1 Billion Euros in New Insulin Production Facility
Sanofi to invest $1 bln in insulin production site in Beijing, local authority says
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics
Sanofi plans to change hospital drug-discount program, WSJ reports
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Source: https://incomestatements.info
Category: Stock Reports